Sophiris Bio Inc. | Ownership
Companies that own Sophiris Bio Inc.
The Vanguard Group, Inc.
1,354,936
4.5%
470,051
0%
06/30/2018
Palo Alto Investors LP
247,000
0.82%
0
0.03%
06/30/2018
Geode Capital Management LLC
211,944
0.7%
192,902
0%
06/30/2018
JPMorgan Securities LLC (Investment Management)
87,768
0.28%
87,767
0%
06/30/2018
Northern Trust Investments, Inc.
80,600
0.27%
60,092
0%
06/30/2018
BlackRock Fund Advisors
74,246
0.25%
2,154
0%
06/30/2018
Budros, Ruhlin & Roe, Inc.
40,000
0.13%
40,000
0.03%
06/30/2018
B&T Capital Management, Inc.
33,728
0.11%
10,500
0.04%
06/30/2018
Susquehanna Financial Group LLLP
26,234
0.09%
-6,953
0%
06/30/2018
The Bank of New York Mellon Corp. (Investment Management)
24,162
0.08%
-12,728
0%
06/30/2018
| Address |
1258 Prospect Street
La Jolla California 92037
United States
|
|
Employees
|
- |
| Website |
http://www.sophirisbio.com |
| Updated |
07/08/2019 |
| Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. It is currently developing PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded by James L. |
